Compound Library Screening
for Candidate Discovery
Candidate compounds are identified in the early stages of the drug development process and selected for evaluation of their potential efficacy and effectiveness as new drugs. This process involves screening within a large compound library to find molecules expected to act on a disease-related target, followed by detailed evaluation and refinement to select the final drug candidate.
Importance of Candidate Selection in New Drug Development
In the early stage of development, work typically begins by screening a compound library—a collection of molecules that serve as the source for prospective drugs. Such libraries can contain several million compounds, from which candidate compounds must be narrowed down. This selection step is critical because it significantly influences the success of subsequent nonclinical and clinical trials.
Computer- and AI-Based Simulations
Prior to nonclinical studies, computer- and AI-based simulations (in silico methods) are widely used to identify compounds with anticipated pharmacological activity, and numerous contract service providers support this work. These methods are integral to pre-evaluating pharmacological activity and related parameters.
Computer- and AI-Based Simulated Testing
Simulated testing using computers and AI is commonly employed to support candidate selection. Based on information about the intended site of action or the relevant pathogen, these methods can assess how strongly a candidate compound binds to its target. High-performance computing systems are used to perform these calculations.
Examples of Contract Service Providers
RIKEN is advancing projects that use AI to conduct efficient lead discovery and optimization, enabling large-scale data analysis and more efficient compound selection. In addition, 薬研社 provides AI-based drug discovery support services that predict how a compound may act on a specific amino acid sequence and support the design of effective compounds.
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.
Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories official website (https://www.smccro-lab.com/jp/)
- SMC Laboratories has established a disease models using patented mouse technologies.
The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
- From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project.
Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
- With flexible small-scale study options and strong technical support, SMC Laboratories is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies
Comprehensive Safety Evaluation for FIH Applications
labcorp
(Labcorp Drug Development)
Reference: labcorp official website (https://jp.labcorp.com/)
- labcorp provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements.
All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
- The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
- labcorp’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials.
For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio
Source: PhoenixBio Official Website (https://phoenixbio.co.jp/)
- PhoenixBio offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
- With advanced LC-MS/MS-based bioanalysis, PhoenixBio provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
- The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics.
For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio delivers unmatched analytical precision and consistency.
Consult Phoenix Bio for PK/PD analysis with a clinical focus
Japanese